RT Journal Article SR Electronic T1 Novel 68Ga-FAPI PET/CT Offers Oncologic Staging Without COVID-19 Vaccine–Related Pitfalls JF Journal of Nuclear Medicine JO J Nucl Med FD Society of Nuclear Medicine SP 368 OP 371 DO 10.2967/jnumed.122.264872 VO 64 IS 3 A1 Tristan T. Demmert A1 Ines Maric A1 Kelsey L. Pomykala A1 Katharina Lueckerath A1 Jens Siveke A1 Benedikt M. Schaarschmidt A1 Rainer Hamacher A1 Ken Herrmann A1 Wolfgang P. Fendler YR 2023 UL http://jnm.snmjournals.org/content/64/3/368.abstract AB In the setting of ongoing coronavirus disease 2019 vaccination, vaccine-related tracer uptake in locoregional lymph nodes has become a well-known issue in tumor staging by 18F-FDG PET/CT. 68Ga-fibroblast-activation protein inhibitor (FAPI) PET/CT is a new oncologic imaging tool that may overcome this limitation. Methods: We assessed postvaccine head-to-head and same-day 18F-FDG and 68Ga-FAPI-46 PET/CT findings in a series of 11 patients from a large, prospective imaging registry. All patients with documented tracer uptake in locoregional lymph nodes on PET/CT or PET/MRI, after vaccination within 6 wk, were eligible for investigation. Result: Significant visual lymph node uptake adjacent to the injection site was noted in 11 of 11 (100%) patients with 18F-FDG PET/CT, versus 0 of 11 (0%) with 68Ga-FAPI PET/CT. 18F-FDG detected 73% and 68Ga-FAPI PET/CT 94% of all tumor lesions. Conclusion: In this case-series study, 68Ga-FAPI showed its potential to avoid 18F-FDG PET/CT postvaccination pitfalls and presented superior tumor localization.